MPM BioImpact LLC - Q3 2023 holdings

$375 Million is the total value of MPM BioImpact LLC's 32 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 58.3% .

 Value Shares↓ Weighting
SellMoonlake Immunotherapeutics$16,768,830
+11.4%
294,190
-0.3%
4.48%
+47.7%
INSM SellInsmed Incorporated$13,318,315
+19.2%
527,458
-0.4%
3.56%
+57.9%
RLAY SellRelay Therapeutics Inc.$11,371,439
-33.2%
1,352,133
-0.2%
3.04%
-11.4%
KRTX SellKaruna Therapeutics Inc$8,997,279
-22.3%
53,210
-0.4%
2.40%
+3.0%
KALV SellKalvista Pharmaceuticals Inc$5,565,736
-18.8%
577,958
-24.1%
1.49%
+7.7%
ONCR ExitOncorus, Inc.$0-2,377,031
-100.0%
-0.02%
ExitVentyx Biosciences Inc$0-31,747
-100.0%
-0.21%
HARP ExitHarpoon Therapeutics, Inc.$0-3,196,707
-100.0%
-0.46%
EWTX ExitEdgewise Therapeutics Inc$0-712,798
-100.0%
-1.11%
RETA ExitReata Pharmaceuticals, Inc.$0-234,478
-100.0%
-4.81%
KDNY ExitChinook Therapeutics, Inc.$0-1,003,406
-100.0%
-7.76%
ISEE ExitIveric Bio Inc$0-1,214,662
-100.0%
-9.62%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Harpoon Therapeutics, Inc.15Q2 202327.6%
Repare Therapeutics, Inc.14Q3 202319.7%
TCR2 Therapeutics, Inc.14Q1 202318.0%
iTeos Therapeutics, Inc.13Q3 202315.7%
G1 Therapeutics, Inc.13Q4 202213.3%
Y Mabs Therapeutics, Inc.12Q3 20225.4%
Cullinan Oncology, Inc.11Q3 202341.4%
Epizyme, Inc.11Q2 202222.1%
Oncorus, Inc.11Q2 202313.3%
Intellia Therapeutics, Inc.10Q3 20235.5%

View MPM BioImpact LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-14
13F-HR2023-08-14
SC 13D/A2023-08-01
SC 13D2023-06-12
42023-06-05
13F-HR2023-05-12
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11

View MPM BioImpact LLC's complete filings history.

Compare quarters

Export MPM BioImpact LLC's holdings